Drug intelligence / Profile preview

PI-166

Development stage: Discontinued
Lead developer: University of New South Wales
Modality: Small Molecules
Administration: Intratumoral

Overview

PI-166 is a small molecule drug initially developed by The University of New South Wales. It is a small organic compound with specific avidity to liver cancer cells and has demonstrated the ability to reduce the growth of rat hepatomas. PI-166 was formulated as a combination of the active compound and a regional delivery vehicle designed to deliver and retain the drug at tumor sites. Its primary therapeutic focus was on neoplasms, particularly liver cancer, but its global highest R&D status is discontinued after reaching Phase 1 clinical trials.

Beyond the preview

Go deeper on PI-166.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PI-166.

Explore the full profile